Investors

Founded in 2000, De Novo has $650 million total assets under management and has made more than 40 investments in medical devices and biotechnology across three funds. De Novo invests in all stages of enterprise development and growth – from early to late stage. For more information, please visit www.denovovc.com.

U.S. Venture Partners (USVP) has helped build great companies for three decades. Since its inception in 1981, USVP has invested over $2.7 billion in about 450 companies. Throughout, USVP's partners have worked diligently and consistently with early-stage companies, many of which have become industry leaders. The USVP team consists of accomplished venture investors, former CEOs, senior executives and technology company founders, who span four generations of high-technology venture investing. This engenders a perspective on business cycles, "hot" market trends, technology evolution and revolution that is not present among all early-stage investors. Together, they have more than 300 years of operating experience and nearly 200 years of investment expertise. For more information, please visit www.usvp.com

Norwest Venture Partners (NVP) is a global venture capital firm that manages more than $3.7 billion in capital. Headquartered in Palo Alto, California, NVP has subsidiaries in Mumbai and Bengaluru, India and Herzelia, Israel. NVP makes early to late stage venture and growth equity investments in U.S. and global companies across a wide range of sectors including: information technology, healthcare, business services, financial services, infrastructure, technology enabled services and consumer. NVP has actively partnered with entrepreneurs to build great businesses for more than 50 years and has funded nearly 500 companies since inception. For more information visit www.nvp.com.